Anixa Biosciences initiates new CAR-T clinical trial

By The Science Advisory Board staff writers

April 1, 2022 -- Anixa Biosciences initiated a phase I trial evaluating its CAR-T cell therapy at the Moffitt Cancer Center.

Anixa's chimeric endocrine receptor T cell (CER T) targets the follicle stimulating hormone receptor, which is expressed on ovarian cells. The CER T will be evaluated for safety and efficacy at the Moffitt Cancer Center in patients with ovarian cancer.

Anixa holds an exclusive, worldwide license for the technology, which was developed at the Wistar Institute.


Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.